We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
RATIONALE Interstitial lung disease ( ILD ) occurs in Japanese patients with non-small cell lung cancer ( NSCLC ) receiving gefitinib .  OBJECTIVES To eluci date risk factors for ILD in Japanese patients with NSCLC during treatment with gefitinib or chemotherapy .  METHODS In a prospect i ve epidemiologic cohort , 3,166 Japanese patients with advanced/recurrent NSCLC were followed for 12 weeks on 250 mg gefitinib ( n = 1,872 treatment periods ) or chemotherapy ( n = 2,551 ) . Patients who developed acute ILD ( n = 122 ) and r and omly selected control subjects ( n = 574 ) entered a case-control study . Adjusted incidence rate ratios were estimated from case-control data by odds ratios ( ORs ) with 95 % confidence intervals ( CIs ) using logistic regression . Crude ( observed ) incidence rates and risks were calculated from cohort data . MEASUREMENTS AND MAIN RESULTS The observed ( unadjusted ) incidence rate over 12 weeks was 2.8 ( 95 % CI , 2.3 - 3.3 ) per 1,000 person-weeks , 4.5 ( 3.5 - 5.4 ) for gefitinib versus 1.7 ( 1.2 - 2.2 ) for chemotherapy ; the corresponding observed naive cumulative incidence rates at the end of 12-week follow-up were 4.0 % ( 3.0 - 5.1 % ) and 2.1 % ( 1.5 - 2.9 % ) , respectively . Adjusted for imbalances in risk factors between treatments , the overall OR for gefitinib versus chemotherapy was 3.2 ( 1.9 - 5.4 ) , elevated chiefly during the first 4 weeks ( 3.8 [ 1.9 - 7.7 ] ) . Other ILD risk factors in both groups included the following : older age , poor World Health Organization performance status , smoking , recent NSCLC diagnosis , reduced normal lung on computed tomography scan , preexisting chronic ILD , concurrent cardiac disease . ILD-related deaths in patients with ILD were 31.6 % ( gefitinib ) versus 27.9 % ( chemotherapy ) ; adjusted OR , 1.05 ( 95 % CI , 0.3 - 3.2 ) . CONCLUSIONS ILD was relatively common in these Japanese patients with NSCLC during therapy with gefitinib or chemotherapy , being higher in the older , smoking patient with preexisting ILD or poor performance status . The risk of developing ILD was higher with gefitinib than chemotherapy , mainly in the first 4 weeks
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV